First Trust Advisors LP Has $41.10 Million Stake in Repligen Co. (NASDAQ:RGEN)

First Trust Advisors LP reduced its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 5.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 285,561 shares of the biotechnology company's stock after selling 15,023 shares during the quarter. First Trust Advisors LP owned 0.51% of Repligen worth $41,104,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. Stifel Financial Corp lifted its stake in Repligen by 5.4% in the 3rd quarter. Stifel Financial Corp now owns 4,404 shares of the biotechnology company's stock worth $655,000 after acquiring an additional 226 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Repligen during the 3rd quarter worth $233,000. Tidal Investments LLC grew its stake in Repligen by 142.8% in the 3rd quarter. Tidal Investments LLC now owns 11,149 shares of the biotechnology company's stock valued at $1,659,000 after buying an additional 6,558 shares during the last quarter. Peapack Gladstone Financial Corp bought a new stake in Repligen during the third quarter valued at about $296,000. Finally, Franklin Resources Inc. grew its position in shares of Repligen by 8.7% in the third quarter. Franklin Resources Inc. now owns 332,405 shares of the biotechnology company's stock valued at $47,551,000 after purchasing an additional 26,668 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Down 6.3 %

Shares of Repligen stock traded down $9.05 during trading on Tuesday, reaching $134.59. 693,472 shares of the company were exchanged, compared to its average volume of 712,822. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The business has a 50-day moving average price of $139.66 and a 200-day moving average price of $145.97. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of -263.73, a P/E/G ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. During the same period in the previous year, the firm posted $0.28 earnings per share. The company's revenue for the quarter was up 10.4% on a year-over-year basis. Sell-side analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax purchased 250 shares of the stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.20% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research note on Monday. HC Wainwright reaffirmed a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. JPMorgan Chase & Co. increased their price target on shares of Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a report on Friday, February 21st. Canaccord Genuity Group decreased their price objective on Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Finally, Evercore ISI initiated coverage on shares of Repligen in a research report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price target for the company. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $176.82.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.